Cipla 2011 / Rohit Deshpande, Sandra J. Sucher & Laura Winig. [Case Study]

By:

Deshpande, Rohit

Contributor(s):

Material type: Text

TextPublication details: Boston, MA : Harvard Business School, 2011.Edition: Revised: July 24, 2012Description: 26 p. : ill. ; 30 cmSubject(s):

Governance Compliance Corporate Strategy Pharmaceutical Industry HIV/AIDS

DDC classification:

CS0010

Summary: Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape.

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Call number	Status	Date due	Barcode
Case Study	Indian Institute for Human Settlements, Bangalore	CS0010 (Browse shelf(Opens below))	Available		CS0010

Browsing Indian Institute for Human Settlements, Bangalore shelves Close shelf browser (Hides shelf browser)

Previous	No cover image available No cover image available	No cover image available No cover image available	No cover image available No cover image available	No cover image available No cover image available	No cover image available No cover image available	No cover image available No cover image available	No cover image available No cover image available	Next
Previous	CS0007 The Aravind eye hospital, Madurai, India :	CS0008 Big Bazaar /	CS0009 Business-driven research at IBM research India /	CS0010 Cipla 2011 /	CS0011 The Dabbawala system:	CS0012 Delhi Metro Rail Corporation /	CS0013 Dharavi:	Next

Includes bibliographical references (p. 23-26).

Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape.

There are no comments on this title.

to post a comment.